Crescent Biopharma, Inc. (CBIO)
| Market Cap | 615.40M |
| Revenue (ttm) | 11.88M |
| Net Income | -162.08M |
| EPS | -5.88 |
| Shares Out | 33.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 549,551 |
| Open | 18.72 |
| Previous Close | 18.76 |
| Day's Range | 17.68 - 19.81 |
| 52-Week Range | 8.72 - 27.41 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 26.67 (+44.01%) |
| Earnings Date | Apr 29, 2026 |
About CBIO
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is head... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CBIO stock is "Strong Buy." The 12-month stock price target is $26.67, which is an increase of 44.01% from the latest price.
News
Crescent Biopharma to Present at May Investor Conferences
WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next w...
Crescent Biopharma reports Q1 EPS (70c), consensus (79c)
Reports Q1 revenue $1.04M, consensus $357,140. “Crescent’s execution on the advancement of our pipeline this quarter positions us for meaningful clinical data readouts in 2027 from CR-001, our potenti...
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination...
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next...
Crescent Biopharma management to meet with Cantor Fitzgerald
Meeting to be held in San Francisco on April 14, in Denver on April 15 and in New York on April 16 hosted by Cantor Fitzgerald.
Crescent Biopharma Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a diversified oncology portfolio, highlighted by a PD-1/VEGF bispecific and multiple ADCs, with a strategic partnership enabling parallel data generation in China and globally. Key clinical readouts are expected in 2027, supported by strong funding and a focus on best-in-class differentiation.
Crescent Biopharma Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing a robust oncology pipeline, highlighted by CR-001 and strategic ADC assets, with multiple studies launching and key data readouts expected in 2027. Strong partnerships and financial position support a data-driven, combination-focused development strategy.
Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Crescent Biopharma (CBIO) to $22 from $25 and keeps a Buy rating on the shares.
Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year
Reports Q4 revenue $10.8M vs .$0 last year. “2025 was a transformational year for Crescent and our efforts to deliver next generation therapies that can improve outcomes for people living…
Crescent Biopharma sees cash runway into 2028
Cash and cash equivalents were $213.2 million as of December 31, 2025, which is anticipated to fund operations into 2028.
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs
Crescent Biopharma to Present at March Investor Conferences
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma announces grants of inducement awards
Crescent Biopharma (CBIO) announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 24,600 shares of the Company’s ordin...
Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial
Crescent Biopharma (CBIO) announced that the first patient has been dosed in its global ASCEND Phase 1/2 clinical trial evaluating CR-001, an investigational PD-1 x VEGF bispecific antibody, for the…
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patient...
Crescent Biopharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
A robust oncology portfolio is advancing with global clinical trials for CR-001 and differentiated ADCs, supported by a strong financial position and strategic partnerships. Key data readouts are expected from 2027, with combination studies and industry catalysts shaping future development.
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Crescent Biopharma (CBIO) with an Overweight rating and $35 price target The firm notes the company’s lead asset CR-001 is a PD-1xVEGF bsAb designed to…
Crescent Biopharma initiated with a Buy at Guggenheim
Guggenheim analyst Brad Canino initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and $35 price target. Crescent is 12-15 months from initial CR-001 data due in Q1 of…
Crescent Biopharma files to sell 19.71M shares of common stock for holders
17:11 EST Crescent Biopharma (CBIO) files to sell 19.71M shares of common stock for holders
Crescent Biopharma announces regulatory clearance of IND applications
Crescent Biopharma (CBIO) announced regulatory clearances of Investigational New Drug applications for CR-001, a PD-1 x VEGF bispecific antibody, and CR-003, an integrin beta-6-targeted antibody drug-...
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-con...
Crescent Biopharma price target raised to $32 from $28 at Stifel
Stifel analyst Stephen Willey raised the firm’s price target on Crescent Biopharma (CBIO) to $32 from $28 and keeps a Buy rating on the shares. The firm believes the Kelun…
Why Is Crescent Biopharma Stock (CBIO) Up Today?
Crescent Biopharma stock gained on Thursday after it revealed a new collaboration and other major updates.
Crescent Biopharma Transcript: Partnership
A strategic partnership with Kelun-Biotech accelerates development of IO and ADC therapies, enabling parallel clinical trials in the US, Europe, and China. Four clinical trials are set for 2026, with multiple data readouts expected in 2027, supported by a $185M capital raise.